Main Article Content


Stroke is still a major health problem in the world. Ischemic stroke accounts for 87% of all acute stroke occurrences. In 2013, the American Heart Association (AHA)/American Stroke Association (ASA), published a Guideline for the Early Management of Patients with Acute Ischemic Stroke. The managements consist of the use of recombinant tissue plasminogen activator (rtPA), endovascular treatment, etc. Unlike acute ischemic stroke, until now, no guidelines have been provided about the management of chronic ischemic stroke that approved universally. The result of the study with the title of “Intra Arterial Heparin Flushing Increases Manual Muscle Test – Medical Research Councils (MMT-MRC) Score in Chronic Ischemic Stroke Patient” is very interesting, because it is a new attempt to treat patients with chronic ischemic stroke. The purpose of this article is to review the study mentioned above, in accordance with the applied scientific principles and is based on the standard literatures and guidelines. Our review is limited only to the discussion of the study results. From this discussion can be proved the existing references that support and/or refuse the study results. Based on the discussions and conclusions of this study, there were no references to support that IAHF can improve motor functions (muscles) in patients with chronic ischemic stroke.


chronic ischemic stroke intra-arterial heparin flusing (IAHF) manual muscle test (MMT) motor function

Article Details

How to Cite
Machfoed, M. H., Kurniawan, M., & Usman, F. S. (2017). Review article: DOES INTRA-ARTERIAL HEPARIN FLUSHING (IAHF) CAN ACTUALLY INCREASE MANUAL MUSCLE TEST (MMT) SCORE IN CHRONIC ISCHEMIC STROKE PATIENTS?. Folia Medica Indonesiana, 52(2), 148–153.


  1. Adams H, Adams R, Del Zoppo G, Goldstein LB (2005). Guidelines for the early management of patients with ischemic stroke. Stroke 36, 916-923
  2. Bhasin A, Srivastava MV, Bhatia R, Mohanty S, Kumaran SS, Bose S (2012). Autologous intravenous mononuclear stem cell therapy in chronic ischemic stroke. J Stem Cells Regen Med 8, 181–189
  3. Chung JW, Kim BJ, Han MK, Ko Y, Lee S, Kang K, Park JM, Park SS, Park TH, Cho YJ, Hong KS, Lee KB, Lee J, Ryu WS, Kim DE, Nah HW, Kim DH, Cha JK, Kim JT, Cho KH, Choi JC, Oh MS, Yu KH, Lee BC, Jang MS, Lee JS, Lee J, Gorelick PB, Yoon BW, Bae HJ; CRCS-5 Investigators (2016). Impact of Guidelines on Clinical Practice: Intravenous Heparin Use for Acute Ischemic Stroke. Stroke 47, 1577-1583
  4. Colucci M, Pentimone A, Binetti BM, Cramarossa M, Piro D, Semeraro N (2002). Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin. Thromb Haemost 88, 282-287
  5. Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, Johnston KC, Starkman S, Morgenstern LB, Wilterdink JL, Levine SR, Saver JL; Joint Stroke Guideline Development Committee of the American Academy of Neurology; American Stroke Association (2002). Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke 33, 1934-1942
  6. Durran AC and Watts C (2012). Current trends in heparin use during arterial vascular interventional radiology. Cardiovasc Intervent Radiol 35, 1308-1314
  7. Dvorak M, Vlasin M, Dvorakova M, Rauser P, Lexmaulova L, Gregor Z, Staffa R (2010). Heparin and its derivatives in the treatment of arterial thrombosis: a review. Veterinarni Medicina 55, 523–546
  8. Eriksson M, Stecksén A, Glader EL, Norrving B, Appelros P, Hulter Åsberg K, Stegmayr B, Terént A, Asplund K; Riks-Stroke Collaboration (2010). Discarding heparins as treatment for progressive stroke in Sweden 2001 to 2008. Stroke 41, 2552-2558
  9. Guggenmos DJ, Azin M, Barbay S, Mahnken JD, Dunham C, Mohseni P, Nudo RJ (2013). Restoration of function after brain damage using a neural prosthesis. Proc Natl Acad Sci U S A 110, 21177-21182
  10. Holleran CL, Straube DD, Kinnaird CR, Leddy AL, Hornby TG (2014). Feasibility and potential efficacy of high-intensity stepping training in variable contexts in subacute and chronic stroke. Neurorehabil Neural Repair 28, 643-651
  11. International Stroke Trial Collaborative Group (1997). The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischemic stroke. Lancet 349, 1569–1581
  12. Izani MSB (2014). Reability of manual muscle test examination of stroke patient in Sardjito Hospital. Bachelor Thesis. University of Gadjah Mada, Yogyakarta
  13. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology (2013). Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44, 870-947
  14. Liu X, Ye R, Yan T, Yu SP, Wei L, Xu G, Fan X, Jiang Y, Stetler RA, Liu G, Chen J (2014). Cell based therapies for ischemic stroke: from basic science to bedside. Prog Neurobiol 115, 92-115
  15. Lundin L, Larsson H, Kreuger J, Kanda S, Lindahl U, Salmivirta M, Claesson-Welsh L (2000). Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. J Biol Chem 275, 24653-24660
  16. Mathers CD and Loncar D (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3, e442
  17. Ministry of Health, Republic of Indonesia (2013). Riskesdas, Jakarta, Health Department, Republic of Indonesia
  18. Mueller RL (2004). First-generation agents: aspirin, heparin and coumarins. Best Pract Res Clin Haematol 17, 23–53
  19. Ockelford PA, Carter CJ, Mitchell L, Hirsh J (1982). Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction. Thromb Res 28, 401-409
  20. Perretti M and Page CP (2000). Heparin and inflammation: a new use for an old GAG? Gut 47, 14–15
  21. Pin-Barre C and Laurin J (2015). Physical exercise as a diagnostic, rehabilitation, and preventive tool: influence on neuroplasticity and motor recovery after stroke. Neural Plast 2015, 608581
  22. Putranto TA, Yusuf I, Murtala B, Wijaya A (2016). Intra arterial heparin flushing increases Manual Muscle Test- Medical Research Councils (MMT-MRC) score in chronic ischemic stroke patient. Bali Medical Journal 5, 25-29
  23. Qureshi AI, Abou-Chebl A, Jovin TG (2008). Qualification requirements for performing neurointerventional procedures: a report of the Practice Guidelines Committee of the American Society of Neuroimaging and the Society of Vascular and Interventional Neurology. J Neuroimaging 18, 433–447
  24. Qureshi AI, Kirmani JF, Sayed MA, Safdar A, Ahmed S, Ferguson R, Hershey LA, Qazi KJ; Buffalo Metropolitan Area and Erie County Stroke Study Group (2005). Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. Neurology 64, 2115–2120
  25. Rödén-Jüllig A and Britton M (2000). Effectiveness of heparin treatment for progressing ischaemic stroke: before and after study. J Intern Med 248, 287–291
  26. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, Elkind MS, George MG, Hamdan AD, Higashida RT, Hoh BL, Janis LS, Kase CS, Kleindorfer DO, Lee JM, Moseley ME, Peterson ED, Turan TN, Valderrama AL, Vinters HV; American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Council on Nutrition, Physical Activity and Metabolism (2013). An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44, 2064-2089
  27. Salas A, Sans M, Soriano A, Reverter JC, Anderson DC, Piqué JM, Panés J (2000). Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 47, 88-96
  28. Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ (2001).Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 32, 2333-2337
  29. Schwerin S (2013). The Anatomy of Movement. Available from 2013/03/05/the-anatomy-of-movement/. Accessed No-vember 15, 2015
  30. Silva-Couto Mde A, Prado-Medeiros CL, Oliveira AB, Alcântara CC, Guimarães AT, Salvini Tde F, Mattioli R, de Russo TL (2014). Muscle atrophy, voluntary activation disturbances, and low serum concentrations of IGF-1 and IGFBP-3 are associated with weakness in people with chronic stroke. Phys Ther 94, 957-967
  31. Usman FS (2013). History of neuro-intervention (Sejarah Neurointervensi). In: Usman FS (ed). Neurointervention Practical Aspect, Jakarta, Balai Penerbit FKUI, p 1-10